Logo image of C43.DE

COSMO PHARMACEUTICALS NV (C43.DE) Stock Fundamental Analysis

FRA:C43 - Deutsche Boerse Ag - NL0011832936 - Common Stock - Currency: EUR

57.5  -2 (-3.36%)

Fundamental Rating

7

C43 gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 52 industry peers in the Pharmaceuticals industry. C43 has an excellent financial health rating, but there are some minor concerns on its profitability. C43 is evaluated to be cheap and growing strongly. This does not happen too often! This makes C43 very considerable for value and growth investing!


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

C43 had positive earnings in the past year.
C43 had a positive operating cash flow in the past year.
In multiple years C43 reported negative net income over the last 5 years.
C43 had a positive operating cash flow in 4 of the past 5 years.
C43.DE Yearly Net Income VS EBIT VS OCF VS FCFC43.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M 100M 150M 200M

1.2 Ratios

The Return On Assets of C43 (10.90%) is better than 82.69% of its industry peers.
C43 has a better Return On Equity (13.96%) than 65.38% of its industry peers.
C43 has a Return On Invested Capital of 10.08%. This is in the better half of the industry: C43 outperforms 63.46% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for C43 is significantly below the industry average of 13.62%.
The last Return On Invested Capital (10.08%) for C43 is above the 3 year average (1.77%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 10.9%
ROE 13.96%
ROIC 10.08%
ROA(3y)1.36%
ROA(5y)-0.29%
ROE(3y)2.3%
ROE(5y)-0.26%
ROIC(3y)1.77%
ROIC(5y)N/A
C43.DE Yearly ROA, ROE, ROICC43.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 40 60

1.3 Margins

Looking at the Profit Margin, with a value of 37.53%, C43 belongs to the top of the industry, outperforming 98.08% of the companies in the same industry.
C43 has a Operating Margin of 46.38%. This is amongst the best in the industry. C43 outperforms 100.00% of its industry peers.
C43's Operating Margin has improved in the last couple of years.
The Gross Margin of C43 (76.47%) is better than 75.00% of its industry peers.
C43's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 46.38%
PM (TTM) 37.53%
GM 76.47%
OM growth 3Y11.6%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.74%
GM growth 5Y-2.8%
C43.DE Yearly Profit, Operating, Gross MarginsC43.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100 200 300 400

More info and screens

9

2. Health

2.1 Basic Checks

C43 has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
Compared to 1 year ago, C43 has less shares outstanding
The number of shares outstanding for C43 has been increased compared to 5 years ago.
Compared to 1 year ago, C43 has an improved debt to assets ratio.
C43.DE Yearly Shares OutstandingC43.DE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M
C43.DE Yearly Total Debt VS Total AssetsC43.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M

2.2 Solvency

An Altman-Z score of 6.23 indicates that C43 is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 6.23, C43 belongs to the best of the industry, outperforming 90.38% of the companies in the same industry.
The Debt to FCF ratio of C43 is 0.01, which is an excellent value as it means it would take C43, only 0.01 years of fcf income to pay off all of its debts.
With an excellent Debt to FCF ratio value of 0.01, C43 belongs to the best of the industry, outperforming 98.08% of the companies in the same industry.
A Debt/Equity ratio of 0.00 indicates that C43 is not too dependend on debt financing.
C43 has a better Debt to Equity ratio (0.00) than 96.15% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0.01
Altman-Z 6.23
ROIC/WACC1.42
WACC7.12%
C43.DE Yearly LT Debt VS Equity VS FCFC43.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M 200M 300M 400M 500M

2.3 Liquidity

A Current Ratio of 4.85 indicates that C43 has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 4.85, C43 belongs to the top of the industry, outperforming 98.08% of the companies in the same industry.
C43 has a Quick Ratio of 4.48. This indicates that C43 is financially healthy and has no problem in meeting its short term obligations.
C43 has a better Quick ratio (4.48) than 98.08% of its industry peers.
Industry RankSector Rank
Current Ratio 4.85
Quick Ratio 4.48
C43.DE Yearly Current Assets VS Current LiabilitesC43.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 549.26% over the past year.
C43 shows a strong growth in Revenue. In the last year, the Revenue has grown by 77.82%.
Measured over the past years, C43 shows a small growth in Revenue. The Revenue has been growing by 7.17% on average per year.
EPS 1Y (TTM)549.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5028.26%
Revenue 1Y (TTM)77.82%
Revenue growth 3Y15.03%
Revenue growth 5Y7.17%
Sales Q2Q%212.03%

3.2 Future

Based on estimates for the next years, C43 will show a very strong growth in Earnings Per Share. The EPS will grow by 25.60% on average per year.
The Revenue is expected to grow by 21.91% on average over the next years. This is a very strong growth
EPS Next Y76.44%
EPS Next 2Y15.45%
EPS Next 3Y-4.08%
EPS Next 5Y25.6%
Revenue Next Year61.12%
Revenue Next 2Y22.68%
Revenue Next 3Y10.3%
Revenue Next 5Y21.91%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
C43.DE Yearly Revenue VS EstimatesC43.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M
C43.DE Yearly EPS VS EstimatesC43.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 10 20 30

More info and screens

8

4. Valuation

4.1 Price/Earnings Ratio

C43 is valuated correctly with a Price/Earnings ratio of 13.31.
Based on the Price/Earnings ratio, C43 is valued cheaply inside the industry as 82.69% of the companies are valued more expensively.
Compared to an average S&P500 Price/Earnings ratio of 29.35, C43 is valued rather cheaply.
C43 is valuated reasonably with a Price/Forward Earnings ratio of 9.74.
Compared to the rest of the industry, the Price/Forward Earnings ratio of C43 indicates a rather cheap valuation: C43 is cheaper than 84.62% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.10. C43 is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 13.31
Fwd PE 9.74
C43.DE Price Earnings VS Forward Price EarningsC43.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

76.92% of the companies in the same industry are more expensive than C43, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, C43 is valued cheaply inside the industry as 88.46% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 10.3
EV/EBITDA 7.93
C43.DE Per share dataC43.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15 20 25

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
C43 has a very decent profitability rating, which may justify a higher PE ratio.
C43's earnings are expected to decrease with -4.08% in the coming years. This may justify a cheaper valuation.
PEG (NY)0.17
PEG (5Y)N/A
EPS Next 2Y15.45%
EPS Next 3Y-4.08%

More info and screens

4

5. Dividend

5.1 Amount

C43 has a Yearly Dividend Yield of 3.47%. Purely for dividend investing, there may be better candidates out there.
Compared to an average industry Dividend Yield of 2.86, C43 pays a bit more dividend than its industry peers.
Compared to an average S&P500 Dividend Yield of 2.33, C43 pays a bit more dividend than the S&P500 average.
Industry RankSector Rank
Dividend Yield 3.47%

5.2 History

Dividend Growth(5Y)N/A
Div Incr Years1
Div Non Decr Years1
C43.DE Yearly Dividends per shareC43.DE Yearly Dividends per shareYearly Dividends per share 2022 2023 2024 2025 0 0 0 0 0

5.3 Sustainability

6.33% of the earnings are spent on dividend by C43. This is a low number and sustainable payout ratio.
DP6.33%
EPS Next 2Y15.45%
EPS Next 3Y-4.08%
C43.DE Yearly Income VS Free CF VS DividendC43.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M 100M 150M 200M
C43.DE Dividend Payout.C43.DE Dividend Payout, showing the Payout Ratio.C43.DE Dividend Payout.PayoutRetained Earnings

More info and screens

COSMO PHARMACEUTICALS NV

FRA:C43 (3/7/2025, 7:00:00 PM)

57.5

-2 (-3.36%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-06 2025-03-06/amc
Earnings (Next)N/A N/A
Inst Owners12.98%
Inst Owner ChangeN/A
Ins Owners38.78%
Ins Owner ChangeN/A
Market Cap1.01B
Analysts84
Price Target103.37 (79.77%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 3.47%
Yearly Dividend1.06
Dividend Growth(5Y)N/A
DP6.33%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.22%
PT rev (3m)-0.95%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-2.66%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0.7%
Revenue NY rev (3m)0.45%
Valuation
Industry RankSector Rank
PE 13.31
Fwd PE 9.74
P/S 5.44
P/FCF 10.3
P/OCF 8.6
P/B 2.02
P/tB 10.09
EV/EBITDA 7.93
EPS(TTM)4.32
EY7.51%
EPS(NY)5.9
Fwd EY10.26%
FCF(TTM)5.58
FCFY9.7%
OCF(TTM)6.69
OCFY11.63%
SpS10.57
BVpS28.42
TBVpS5.7
PEG (NY)0.17
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 10.9%
ROE 13.96%
ROCE 14.32%
ROIC 10.08%
ROICexc 12.96%
ROICexgc 88.37%
OM 46.38%
PM (TTM) 37.53%
GM 76.47%
FCFM 52.8%
ROA(3y)1.36%
ROA(5y)-0.29%
ROE(3y)2.3%
ROE(5y)-0.26%
ROIC(3y)1.77%
ROIC(5y)N/A
ROICexc(3y)2.8%
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)2.52%
ROCE(5y)N/A
ROICexcg growth 3Y102.47%
ROICexcg growth 5YN/A
ROICexc growth 3Y16.96%
ROICexc growth 5YN/A
OM growth 3Y11.6%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.74%
GM growth 5Y-2.8%
F-Score9
Asset Turnover0.29
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0.01
Debt/EBITDA 0.01
Cap/Depr 132.86%
Cap/Sales 10.5%
Interest Coverage 39.31
Cash Conversion 116.6%
Profit Quality 140.68%
Current Ratio 4.85
Quick Ratio 4.48
Altman-Z 6.23
F-Score9
WACC7.12%
ROIC/WACC1.42
Cap/Depr(3y)91.84%
Cap/Depr(5y)142.07%
Cap/Sales(3y)12.24%
Cap/Sales(5y)15.54%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)549.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5028.26%
EPS Next Y76.44%
EPS Next 2Y15.45%
EPS Next 3Y-4.08%
EPS Next 5Y25.6%
Revenue 1Y (TTM)77.82%
Revenue growth 3Y15.03%
Revenue growth 5Y7.17%
Sales Q2Q%212.03%
Revenue Next Year61.12%
Revenue Next 2Y22.68%
Revenue Next 3Y10.3%
Revenue Next 5Y21.91%
EBIT growth 1Y217.59%
EBIT growth 3Y28.38%
EBIT growth 5YN/A
EBIT Next Year119.88%
EBIT Next 3Y7.1%
EBIT Next 5Y41.25%
FCF growth 1Y1127.39%
FCF growth 3Y55.18%
FCF growth 5YN/A
OCF growth 1Y656.84%
OCF growth 3Y37.32%
OCF growth 5YN/A